Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..
CAR T Cell therapy trials, Glioblastoma, glioblastoma trials, gliomas
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
American Society of Hematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..
Daiichi Sankyo, DESTINY-Breast04, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer
August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting or experienced a disease recurrence during or within six..
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
Olaparib is approved for adjuvant treatment of high-risk early breast cancer
March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) h..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Drugs approved for treatment of liver cancer
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, KRAS G12C, Lumakras, NSCLC, sotorasib
The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant
August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with non-small cell lung cancer who have undergone at least one prior system..
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, RECIST, USFDA
Pembrolizumab is approved by FDA for adjuvant treatment of melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablynx, ADAMTS13, CABLIVI, caplacizumab-yhdp, FDA, immunosuppressive therapy, USFDA
Caplacizumab-yhdp approved by FDA
On February 6, 2019, in conjunction with plasma exchange and immunosuppressive treatment, the Food and Drug Administration approved caplacizumab-yhdp (CABLIVI, Ablynx NV) for adult patients with acquired thrombotic thrombocytopeni..